TPST AI Stock Analysis – Buy, Hold, or Avoid?
Tempest Therapeutics, Inc. (TPST)
Tempest Therapeutics (TPST) is a clinical-stage biotech with no revenue, significant net losses, and severe liquidity constraints. The stock trades near its 52-week low with bearish technicals and mixed sentiment. While the valuation is deeply discounted reflecting financial distress, upside depends heavily on successful clinical trial outcomes and capital raises. Given high execution and funding risks, investors should wait for clearer signs of pipeline progress or financial stabilization before committing.
Fundamentals
Tempest Therapeutics Inc. operates as a clinical-stage biotechnology company with zero revenue and sustained net losses driven primarily by research and development and administrative expenses. The company shows significant volatility in earnings, marked by widening losses particularly in earlier quarters, though recent data suggest some moderation. Despite its development focus, limited financial resources and deteriorating operating metrics present considerable challenges.
Financial Highlights
Growth Metrics
Profitability Metrics
Technical Analysis
TPST is currently in a pronounced downtrend, trading near its 52-week low with a strong bearish technical setup. Momentum remains subdued with the RSI in a neutral zone, but price action confirms a decline phase with significant moving average resistance overhead. There is little evidence of a reversal yet, and key supports are being tested with weak trend strength indicated by ADX.
Earnings
Tempest Therapeutics Inc. operates as a clinical-stage biotechnology company with zero revenue and sustained net losses driven primarily by research and development and administrative expenses. The company shows significant volatility in earnings, marked by widening losses particularly in earlier quarters, though recent data suggest some moderation. Despite its development focus, limited financial resources and deteriorating operating metrics present considerable challenges.
Valuation
Tempest Therapeutics (TPST) is currently trading at a very depressed valuation within the volatile biotechnology sector, reflecting its late-stage development status, lack of revenue, and significant net losses. Despite bearish technical signals and financial stress concerns, analyst consensus leans towards a strong buy with substantial upside price targets driven by promising clinical data and potential future breakthroughs.
Sentiment & Analyst Ratings
The overall sentiment for TPST stock is mixed with cautious investor sentiment driven by recent financing activities, governance enhancements, and partnership expansions juxtaposed against a persistent depressed share price and lowered analyst price targets. News and analyst ratings reflect a cautious to negative bias, while social media signals bearish retail sentiment tempered by speculative short squeeze discussions and buyout hopes.
Risk Assessment
Tempest Therapeutics exhibits significant financial stress characterized by low liquidity and high leverage, coupled with ongoing operational challenges and capital needs. The company's risk profile is elevated due to clinical trial uncertainties, dilutive financing, and sector-wide regulatory headwinds, making it a high-risk investment in biotechnology. Investors should weigh the potential reward of its pipeline against the substantial risk of dilution and volatility.
Frequently Asked Questions about TPST
AI Answers: Common Questions About TPST
Get AI-powered answers to the questions investors ask most about Tempest Therapeutics, Inc.
Currently, TPST is not a good buy for most investors due to zero revenue, large net losses, and severe liquidity issues. The stock trades near its 52-week low at $0.62 with bearish technicals. Only highly speculative investors comfortable with biotech risk should consider it.
Short-term traders should consider selling or avoiding new positions given the strong downtrend and lack of reversal signals. Long-term holders may hold but should monitor clinical and financial developments closely.
Main risks include severe liquidity constraints (current ratio below 1), high dilution from frequent capital raises, clinical trial failures, regulatory hurdles, and negative equity indicating solvency concerns.
Analyst price targets have been lowered from $11 to around $7, reflecting tempered expectations. Resistance levels at $0.93, $1.31, and $1.62 are key technical price points to watch.
Valuation is deeply undervalued with a negative P/E ratio (-0.15) and low price-to-book ratios, justified by the lack of revenue and ongoing losses but supported by potential pipeline value and partnerships.
Fundamentals show no revenue, volatile and negative EPS (recently -$0.34), high R&D expenses, and deteriorating liquidity. The company is pre-commercial and reliant on external funding.
Technically, TPST is in a strong downtrend with price below all major moving averages and a death cross present. Momentum is weak with RSI near 34 and ADX indicating weak trend strength. No reversal patterns are evident.
Key catalysts include clinical trial updates, partnership announcements (e.g., Roche collaboration), financing rounds, and potential acquisition activity following the poison pill expiry.
Want a Personalized Answer?
Get AI-powered insights tailored to your risk tolerance and investment goals.